Epirubicin Suppliers & Bulk Manufacturers
Available Forms: Injection
Available Strengths: 10 mg/5 mL, 50 mg/25 mL, 200 mg/100 mL
Reference Brands: Ellence®(US); Farmorubicin®(EU)
Category:
Oncology Cancer Care
Epirubicin is an anthracycline chemotherapy injection used in breast, bladder, and gastric cancers, available in multiple vial strengths across the US and EU.
Epirubicin is available in Injection
and strengths such as 10 mg/5 mL, 50 mg/25 mL, 200 mg/100 mL.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Epirubicin is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Epirubicin can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Epirubicin Hydrochloride is a widely used oncology injectable in the US and EU, primarily indicated for breast cancer, gastric cancer, and bladder cancer. It is a potent anthracycline chemotherapy agent that interferes with DNA replication, leading to cancer cell death. Available in concentrations like 2 mg/mL across multiple vial sizes, Epirubicin offers versatility for intravenous and intravesical administration. Approved under several brands, including Farmorubicin®, it is a key component in combination regimens. Pharmaceutical B2B buyers and distributors in the EU and US recognize Epirubicin as a high-demand, regulated oncology product with broad market application.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing